Medas Fabio, Canu Gian Luigi, Cappellacci Federico, Anedda Giacomo, Conzo Giovanni, Erdas Enrico, Calò Pietro Giorgio
Department of Surgical Sciences, University of Cagliari, 09124 Cagliari, Italy.
Division of General and Oncologic Surgery, Department of Cardiothoracic Sciences, University of Campania "Luigi Vanvitelli", 80131 Naples, Italy.
Cancers (Basel). 2020 Jun 23;12(6):1658. doi: 10.3390/cancers12061658.
The role of prophylactic central lymph node dissection (pCLND) in the treatment of differentiated thyroid cancer (DTC) is controversial and still a matter of debate. The primary outcome of our study was to assess whether pCLND is effective in reducing the incidence of recurrent disease, and the secondary goal was to estimate the incidence of postoperative complications in patients who underwent pCLND and to evaluate the prognostic value of occult node metastases. In this retrospective study, we included patients with preoperative diagnosis of DTC and clinically uninvolved lymph nodes (cN0). The patients were divided into two groups, depending on the surgical approach: total thyroidectomy alone (TT group) or total thyroidectomy and pCLND (pCLND group). Three hundred and ninety-nine patients were included in this study, 320 (80.2%) in the TT group and 79 (19.8%) in the pCLND group. There were no significant differences in morbidity among the two groups. Histopathological evaluation demonstrated a similar distribution of aggressive features, especially regarding multicentricity, extrathyroidal extension, and angioinvasivity between the two groups. Occult lymph node metastases were found in 20 (25.3%) patients in the pCLND group. Prophylactic CLND was effective in improving disease-free survival in patients with intermediate and high risk of disease recurrence ( = 0.0392); occult lymph node metastases resulted as a significant negative prognostic factor ( < 0.001).
预防性中央区淋巴结清扫术(pCLND)在分化型甲状腺癌(DTC)治疗中的作用存在争议,仍是一个备受争论的问题。我们研究的主要结果是评估pCLND在降低疾病复发率方面是否有效,次要目标是估计接受pCLND患者的术后并发症发生率,并评估隐匿性淋巴结转移的预后价值。在这项回顾性研究中,我们纳入了术前诊断为DTC且临床未累及淋巴结(cN0)的患者。根据手术方式将患者分为两组:单纯甲状腺全切除术(TT组)或甲状腺全切除术加pCLND(pCLND组)。本研究共纳入399例患者,TT组320例(80.2%),pCLND组79例(19.8%)。两组之间的发病率无显著差异。组织病理学评估显示两组侵袭性特征分布相似,尤其是在多中心性、甲状腺外侵犯和血管侵犯方面。pCLND组有20例(25.3%)患者发现隐匿性淋巴结转移。预防性CLND对疾病复发中高危患者的无病生存期改善有效( = 0.0392);隐匿性淋巴结转移是一个显著的不良预后因素( < 0.001)。